Yanyin Tech and CirCode Biomed Forge Three-Year RNA Drug Development Partnership
Yanyin Tech and Shanghai CirCode Biomed Co. Ltd. have announced a three-year strategic cooperation agreement...
Fineline Cube
China Resources Double-Crane Partners with Rigerna on siRNA Drug RG008 for Chronic Metabolic Diseases
China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) and Suzhou Rigerna Therapeutics have entered into...
Livzon Launches China’s First Oral GnRH Antagonist for Multiple Indications
Livzon Pharmaceutical Group Inc. (HKG: 1513), a China-based company, announced on September 10, 2025, the...
Pacific Shuanglin’s Controlling Stake Transferred to CNBG in RMB 4.7B Deal
Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE: 000403), a China-based blood products company, announced that its...
Jingze Bio and CMS Subsidiary Partner to Commercialize Key Products in Reproduction and Ophthalmology
On September 12, 2025, Jingze Biopharmaceutical (Hefei) Co., Ltd., based in China, and a subsidiary...
Sino Biopharmaceutical’s Partner CTTQ Secures Breakthrough Therapy Designation for TQ‑B3234 Capsule in China
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of China‑based Sino Biopharmaceutical Ltd. (HKG: 1177), today...
Pfizer Reports Positive Phase 3 HER2CLIMB‑05 Results for TUKYSA (Tucatinib) in First‑Line HER2+ MBC
Pfizer Inc. (NYSE: PFE) today announced compelling topline results from the Phase 3 HER2CLIMB‑05 trial, evaluating...
Zennova & Rapafusyn Forge Alliance to Accelerate Non‑Degrading Molecular Glue Therapies
Zennova Pharmaceutical announced today a strategic partnership with U.S.‑based biotech Rapafusyn Pharmaceuticals to jointly develop...
Shenzhen Kangtai Secures 530 Million Yuan Technology Transfer for Klebsiella Pneumoniae Vaccine
Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) today announced the signing of a technology‑transfer...
Eisai & Biogen Secure TGA Approval for Lecanemab (Leqembi) in Early Alzheimer’s Disease
Japanese pharmaceutical giant Eisai Co., Ltd. (TYO: 4523) and U.S. biopharma Biogen Inc. (NASDAQ: BIIB)...
GenScript’s ProBio Secures RMB 479.7 M License Payment for LM‑299, Boosting SinoBiopharmaceutical’s Portfolio
GenScript Biotech Corporation (HKG: 1548) today announced that its Contract‑Development‑and‑Manufacturing‑Organization (CDMO) platform, ProBio, received a...
Chengdu Olymvax Biopharmaceuticals & Delonix Bioworks Announce Joint Development of Gene‑Engineered Pertussis Vaccine
Chengdu Olymvax Biopharmaceuticals Inc. and Delonix Bioworks Co., Ltd. today announced a strategic collaboration and...
Jiudian Pharma Acquires Chengdu Peide’s JIJ02 Gel, Advancing a Novel Acne Treatment into Phase 1
Hunan Jiudian Pharmaceutical Co., Ltd. (SHE: 300705) today announced the acquisition of all developed results...
Junshi Biosciences Reports 49 % YoY Revenue Growth in H1 2025, Raises Cash Reserves to RMB 3.49 B
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) today released its 2025 interim financial...
Johnson & Johnson Reports Robust Q3 2025 Sales Growth, Boosts Full‑Year Outlook
Johnson & Johnson (J&J, NYSE: JNJ) announced its third‑quarter results for 2025, showing a 5.4 %...
Kailera Therapeutics Secures $600 Million Series B Funding from Bain Capital Private Equity to Accelerate Global Obesity Pipeline
Kailera Therapeutics, Inc., the Delaware‑registered spin‑off of Hengrui Pharma, today announced the closing of a...
Bio‑Thera Expands Canadian Partnership with Intas Pharma for Golimumab Biosimilar BAT2506
Bio‑Thera Solutions (SHA: 688177) today announced the expansion of its collaboration with Intas Pharmaceuticals for...
National Joint Procurement Office Announces 11th Round VBP, AstraZeneca Dapagliflozin Leads Demand
On October 11, 2025, the National Joint Procurement Office (NJPO) released the full company list for...
Maxvax Biotech Secures NMPA Acceptance for Its Recombinant Herpes Zoster Vaccine
Maxvax Biotech announced today that the China National Medical Products Administration (NMPA) has accepted the...